Key OpinionGlycaemic control and weight reduction in type 2 diabetes with weekly tirzepatide, a novel GIP/GLP-1 agonist (dummy 38)
Key OpinionGlycaemic control and weight reduction in type 2 diabetes with weekly tirzepatide, a novel GIP/GLP-1 agonist
Key OpinionRethinking treatment adherence: what the latest gastroenterology and hepatology evidence shows